ONS-5010, an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD, demonstrated safety and efficacy profile consistent with previously published ophthalmic bevacizumab research NORSE 1 results support trial design and inclusion criteria for fully enrolled, ongoing

Successfully completed NORSE 2 enrollment in July 2020 NORSE 1 topline results to be reported in August 2020 MONMOUTH JUNCTION, N.J. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first

MONMOUTH JUNCTION, N.J. , July 17, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the successful

Pivotal NORSE 2 safety and efficacy data expected to be reported in the third calendar quarter of 2021   ONS-5010 / LYTENAVA ™   (bevacizumab-vikg)   has the potential to be the first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications MONMOUTH JUNCTION, N.J.

MONMOUTH JUNCTION, N.J. , June 25, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“the Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that

MONMOUTH JUNCTION, N.J. , June 23, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“the Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that

Lead product candidate ONS-5010 / LYTENAVA TM   (bevacizumab-vikg)   has potential to be first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications   Topline results from NORSE 1, the Company’s first registration clinical trial evaluating ONS-5010 and providing

MONMOUTH JUNCTION, N.J. , June 11, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today that

Live moderated video webcast discussion with President, CEO and CFO Lawrence Kenyon, on Wednesday, June 17th at 2:00 PM ET, immediately followed by an interactive Q&A session MONMOUTH JUNCTION, N.J. , June 09, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

MONMOUTH JUNCTION, N.J. , June 03, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the